Searched for
ZYDUS GROUP
Zydus Lifesciences, 2 other share buybacks closing today. Are you participating?Investors have a final opportunity to tender shares in buyback offers from Zydus Lifesciences, Dhanuka Agritech, and CyberTech Systems and ...- India’s consumer demand remains resilient despite Iran war, inflation pressures; FMCG firms stay cautiously optimisticDespite geopolitical turmoil and inflation, domestic consumption of essentials and personal care products remains resilient. Company execut...
- From Tata to tech giants, Indian companies tighten grip on UK economyIndian businesses are significantly expanding their UK presence, with company numbers soaring by nearly 60% and combined revenues exceeding...
- Wockhardt secures US FDA approval for antibiotic ZaynichWockhardt's novel antibiotic, Zaynich (cefepime and zidebactam), has received US FDA approval for complicated urinary tract infections. Thi...
- Zydus Lifesciences buyback alert! Last date to buy shares to participate in Rs 1,100 crore buyback at 7% premiumInvestors must purchase Zydus Lifesciences shares by Wednesday, May 27, to be eligible for the Rs 1,100 crore buyback, as the record date i...
- Zydus Lifesciences' Rs 1,100 crore share buyback at 13% premium: Check record date, other detailsZydus Lifesciences is launching its largest share buyback program to date. The company plans to repurchase shares worth Rs 1,100 crore. Thi...
- Tata group’s Impetis out-licenses arthritis and autoimmune drugs to VyomeIn a significant move for medical innovation, Impetis Biosciences, a subsidiary of Tata group, has teamed up with Vyome Holdings from the U...
- Semaglutide race: Torrent grabs 38% market shareOver a dozen Indian companies have launched generic versions of the GLP1 drug used for diabetes and weight management since the expiry of N...
- Zydus Biologics’ Ahmedabad injectable facility gets 7 observations in USFDA inspectionZydus Lifesciences has made headlines as its Zydus Biologics injectable plant in Ahmedabad underwent a USFDA inspection between April 27 an...
- Bain Capital sole contender for Vitabiotics buyBain Capital has emerged as the frontrunner to acquire Vitabiotics, as rival bidders TPG Capital and EQT exit the process, potentially lowe...
- Semaglutide API price plunges amid GLP-1 rushGlobal demand for weight-loss drugs Ozempic and Wegovy has caused semaglutide prices to drop significantly. Manufacturing has expanded rapi...
- Mounjaro sales dip amid price war as semaglutide generics gain groundMounjaro, the star pharmaceutical from Eli Lilly, is experiencing a downturn in sales across India. This slump can be attributed to competi...
- Zydus Group to invest Rs 5,000 cr in GujaratZydus Group plans to invest Rs 5,000 crore in Gujarat, including biotechnology products and hospitals. Memoranda of Understanding (MoUs) ha...
- Hope to start supply of ZyCoV-D vaccine by mid to end September: Zydus Group MD"Post the emergency use authorisation, now we will work closely with the regulatory authorities to work on the pricing and modality of deli...
- Maruti Suzuki sets up multi-specialty hospital at Sitapur in GujaratManaged and operated by Ramanbhai Foundation, the CSR arm of Zydus Group, the hospital is also assisting in taking care of Covid-19 patient...
- Zydus Group clinches in-licensing deal with Swiss company Neovii"The Zydus group will market this therapy through Zydus Trans-immune, a division that offers a range of therapies related to transplant med...
- Zydus group inks pact with Eczacibasi to market biotech productsThe collaboration agreement involves the import of bio-similars that are currently unavailable in Turkey, especially for the treatment of c...
- Zydus ties up with US-based research centre NIAD to develop vaccineThe Group employs over 16,500 people worldwide, including over 1,600 scientists in R&D. Cadila Healthcare is part of Zydus Group.
- Zydus launches diabetes treatment drug LipaglynPharmaceutical entity Zydus group on Monday said it has launched Lipaglyn, its patented new drug for treatment of diabetes.
- Cadila Healthcare Q3 net dips by 4.4%, sales rise 20%Cadila Healthcare, the flagship company of Zydus group, has suffered a 4.4% drop in its third quarter net profit on account of forex losses.
Load More
